Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents.
Margherita GobboJamie JoyHelena GuedesMuhammad Ali ShazibCarryn AndersonRagda Abdalla-AslanKhunthong PeechatananCarlo LajoloKhawaja Shehryar NasirLuiz Alcino GueirosNivethitha NagarajanKimia Hafezi MotlaghAbhishek KandwalCosimo RupeYuanming XuEli D EhrenpreisArghavan TonkaboniJoel B EpsteinPaolo BossiHannah R WardillStephanie L GraffPublished in: Expert opinion on pharmacotherapy (2024)
The discovery of more precise pathophysiologic mechanisms of CT and RT-induced OM has outlined that OM has a multifactorial origin, including direct effects, oxidative damage, upregulation of immunologic factors, and effects on oral flora. A persistent upregulated immune response, associated with factors related to patients' characteristics, may contribute to more severe and long-lasting OM. The goal is strategies to conjugate individual patient, disease, and therapy-related factors to guide OM prevention or treatment. Despite further high-quality research is warranted, the issue of prevention is paramount in future strategies.
Keyphrases
- immune response
- end stage renal disease
- ejection fraction
- newly diagnosed
- small molecule
- chronic kidney disease
- computed tomography
- cancer therapy
- peritoneal dialysis
- prognostic factors
- high glucose
- drug induced
- poor prognosis
- magnetic resonance imaging
- cell proliferation
- squamous cell carcinoma
- dendritic cells
- high throughput
- diabetic rats
- early onset
- current status
- radiation therapy
- patient reported outcomes
- locally advanced
- magnetic resonance
- mesenchymal stem cells
- replacement therapy
- bone marrow
- patient reported